Corbus Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Corbus Pharmaceuticals (CRBP).

Price Target Range — 11 Quarters

Analyst Consensus — 10 Analysts

10Buy

Consensus RatingBuy# Analysts10Avg. Consensus PT$43Upside to Avg. PT+988.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 14, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$35
Aug 7, 2026	Oppenheimer	Jeff Jones	PT Cut	Outperform	$52→$48
Aug 7, 2026	HC Wainwright & Co.	Andres Y. Maldonado	PT Cut	Buy	$40→$35
Jun 23, 2026	Mizuho	Graig Suvannavejh	PT Cut	Outperform	$44→$34
Jun 17, 2026	Oppenheimer	Jeff Jones	PT Cut	Outperform	$54→$52
May 27, 2026	Wedbush	Robert Driscoll	PT Cut	Outperform	$38→$30
May 26, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$40
May 22, 2026	Mizuho	Graig Suvannavejh	PT Raise	Outperform	$40→$44
May 13, 2026	Jefferies	Maury Raycroft	PT Cut	Buy	$36→$33
May 13, 2026	Oppenheimer	Jeff Jones	PT Cut	Outperform	$57→$54
May 13, 2026	Guggenheim	Paul Jeng	Maintained	Buy	$45
Apr 29, 2026	Guggenheim	Paul Jeng	Initiate	Buy	$45
Mar 10, 2026	Oppenheimer	Jeff Jones	PT Raise	Outperform	$53→$57
Nov 13, 2025	RBC Capital	Brian Abrahams	PT Cut	Outperform	$55→$53
Oct 20, 2025	Wedbush	Robert Driscoll	PT Raise	Outperform	$31→$38
Oct 20, 2025	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$40
Sep 17, 2025	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$40
Aug 6, 2025	Oppenheimer	Jeff Jones	PT Cut	Outperform	$56→$53
May 7, 2025	RBC Capital	Brian Abrahams	PT Cut	Outperform	$65→$58
May 7, 2025	Oppenheimer	Jeff Jones	PT Cut	Outperform	$60→$56

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $35 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $35 price target.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $48

Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $52 to $48.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $35

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and lowers the price target from $40 to $35.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $34

Mizuho analyst Graig Suvannavejh maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $44 to $34.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $52

Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $54 to $52.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $30

Wedbush analyst Robert Driscoll maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $38 to $30.

Benzinga Newsdesk

Corbus Pharmaceuticals Holdings Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Corbus Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $35 Price Target

PRO
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $48

PRO
HC Wainwright & Co. Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $35

PRO
Mizuho Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $34

PRO
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $52

PRO
Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $30

People Also Watch

People Also Watch

Corbus Pharmaceuticals Holdings Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Corbus Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $35 Price Target

PROOppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $48

PROHC Wainwright & Co. Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $35

PROMizuho Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $34

PROOppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $52

PROWedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $30

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $35 Price Target

PRO
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $48

PRO
HC Wainwright & Co. Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $35

PRO
Mizuho Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $34

PRO
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $52

PRO
Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $30